CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 8 enrolled
Drug / intervention
JULUCA 50Mg-25Mg Tabletdrug
Likely dose
JULUCA 50Mg-25Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04431518
NCT04431518Phase 4Completed
CompareCT.gov

The Steady-State Pharmacokinetics (PK) of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis (HD)

Indiana University·interventional·Posted Jun 16, 2020·Updated Jun 5, 2024

In Brief

A Phase 4 clinical trial evaluating JULUCA 50Mg-25Mg Tablet for HIV/AIDS and ESRD. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study will compare the pharmacokinetics of the component drugs in JULUCA, and HIV combination treatment pill, in HIV-negative patients who require hemodialysis with those with normal renal function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS, ESRD
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 16, 2020
Enrollment StartApr 23, 2021
Primary CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.0 years ago

Interventions

JULUCA 50Mg-25Mg Tabletdrug

One dose of JULUCA will be taken daily for up to 14 days